The guidance encourages the use of Bayesian statistics in drug trials. Instead of starting from scratch and only adding new ...

The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...

Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development ...

Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company ...

The FDA declined to review Moderna’s experimental flu vaccine over trial design concerns, despite no safety issues. The ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

The clinical-stage siRNA biopharmaceutical company announced that its INTASYL compound PH-762 achieved an 85% pathological ...

Investing.com-- Moderna Inc (NASDAQ: MRNA ) shares fell sharply in aftermarket trade on Tuesday after it said the U.S. Food and Drug Administration had refused to review its influenza vaccine ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript February 9, 2026 Anavex Life Sciences Corp. beats ...

Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.